Overcoming delays to accessing NICE approved treatment: NICE chairman discusses the case of dexamethasone intravitreal implants (Ozurdex)

Source: HSJ
Area: News
In this article in the Health Service Journal, Michael Rawlins discusses the delay in accessing treatments approved by NICE, using the case of dexamethasone intravitreal implants (Ozurdex) for the treatment of retinal vein occlusion as an example. He describes a meeting with the head of policy and campaigns at the Royal National Institute of Blind People (RNIB) about the availability of these implants which had been considered by NICE in July 2011 to represent a cost-effective use of NHS resources. However, when the RNIB contacted 125 (Read more...)

Full Story →